Tier 4 — mechanistic

Inhibition of c-Jun N-terminal kinase and nuclear factor κ B pathways mediates fisetin-exerted anti-inflammatory activity in lipopolysaccharide-treated RAW264.7 cells

Kim SC, Kang SH, Jeong SJ, Kim SH, Ko HS, Kim SH
Immunopharmacology and Immunotoxicology 2012 34(4):645-50

Bibliography

PubMed
PMID 22239491
DOI
10.3109/08923973.2011.648270
Funding
Not explicitly stated in the reviewed sections; conducted at the College of Oriental Medicine, Kyung Hee University, Seoul, South Korea.
Competing interests
Not stated in the reviewed sections.

Study snapshot

DesignLPS-stimulated RAW264.7 mouse macrophage cells pretreated with fisetin, assessing nitric oxide production, iNOS/COX-2 expression, pro-inflammatory cytokine secretion, and NF-κB and MAPK (JNK, ERK, p38) activation.
ModelRAW264.7 mouse macrophage cell line, LPS-stimulated in vitro.
SampleStandard in vitro cell-culture replicate design; exact n not stated in the reviewed abstract.
InterventionFisetin pretreatment of RAW264.7 cells prior to LPS stimulation (concentration range not fully specified in reviewed sections).
DurationStandard short-term in vitro LPS-stimulation assay (typically pretreatment followed by 18-24 h LPS exposure).
EndpointsNitric oxide production (Griess assay); iNOS and COX-2 protein/mRNA expression; IL-6 and TNF-alpha secretion; NF-κB activation; Phosphorylation of JNK, ERK and p38 MAPK

What the study showed, in plain terms

Macrophages are immune cells that drive much of the body's inflammatory response, and this study examined exactly which signalling pathway fisetin uses to calm them down.

Korean researchers exposed mouse macrophage cells to a bacterial toxin (LPS) to trigger inflammation, with or without fisetin pretreatment, and traced the effect back to specific signalling proteins.

Fisetin reduced nitric oxide production and lowered iNOS, COX-2, IL-6 and TNF-alpha. It suppressed NF-κB activation and blocked phosphorylation of JNK specifically, while leaving ERK and p38 MAPK activity unaffected — pinpointing JNK and NF-κB, not the broader MAPK family, as the relevant anti-inflammatory pathway.

Bottom line: a narrowly-scoped but mechanistically precise cell-culture study; useful for understanding fisetin's anti-inflammatory pathway specificity, but it offers no dosing or in vivo efficacy information.

Key findings

Fisetin significantly reduced LPS-induced nitric oxide production, iNOS and COX-2 expression, and IL-6/TNF-alpha secretion in RAW264.7 macrophages, acting through suppression of NF-κB activation and JNK phosphorylation specifically, with no effect on ERK or p38 MAPK phosphorylation.

What this study can and cannot tell us

In vitro, single cell-line study (RAW264.7 macrophages); no animal or human data to confirm the anti-inflammatory mechanism translates in vivo. Fisetin concentrations and precise treatment timing are not detailed in the reviewed abstract.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology